Latest Breaking News On - Chief financial officer costa saroukos - Page 1 : comparemela.com

Takeda drops cancer candidates amid shifting treatment landscape

Takeda drops cancer candidates amid shifting treatment landscape
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Christophe weberMemorial sloan kettering cancer center partneredMaverick therapeuticsChief financial officer costa saroukos

Takeda Pharmaceutical s Third-Quarter Net Profit Dropped on Lower Margins -- Update

By Kosaku Narioka Takeda Pharmaceutical reported a drop in its third-quarter net profit due partly to lower margins despite some growth in revenue. The Japanese drugmaker said Thursday.

Kosaku nariokaChief financial officer costa saroukosMilano furutaDow jones

Takeda s Japan plant reemerges from FDA warning letter as pharma works through pipeline setbacks

Over a year into a stunning FDA warning letter, Takeda has resolved manufacturing problems at home as it gears up to make Novavax’s COVID-19 vaccine for Japan.

Christophe weberMasato iwasakiJapanese hikariAndy plumpChief financial officer costa saroukosChristophe weberUsfda warning letterCovid 19Vaccine manufacturingInflammatory bowel diseasePharma asiaDrug delivery

Takeda offloads heart and metabolism drugs to 3-month-old Chinese firm for $322M

Dec 23, 2020 9:47am Takeda is selling five cardiovascular and metabolism drugs in the Chinese market to local company Hasten Biopharmaceutic for $322 million. (Takeda) Takeda has already exceeded the product sell-off goal it set alongside its Shire merger, but the Japanese pharma shows no sign of slowing down. After making several geography-specific divestitures in different regions of the world, Takeda has turned to China. The company said Monday it agreed to offload some cardiovascular and metabolic drugs in the Chinese mainland to local firm Hasten Biopharmaceutic for $322 million. The deal covers five drugs, including hypertension med Ebrantil (urapidil); the whole portfolio generated $109.5 million in sales for the fiscal year ended in March.

Ricardo marekHasten biopharmaceuticOptimal scale upTech transferMoral smallChief financial officer costa saroukosSouth koreaSome europeanAsia pacificRay capital managementGray capitalரிக்கார்டோ மரேக்உகந்த அளவு மேலேதொழில்நுட்பம் பரிமாற்றம்வாய்வழி சிறியதெற்கு கொரியா